(Q54111832)

24 May 2018

title

Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. (English)

1 reference

24 May 2018

main subject

phase I clinical trial

0 references

author name string

R Stupp

1

1 reference

24 May 2018

J Bauer

2

1 reference

24 May 2018

O Pagani

3

1 reference

24 May 2018

B Gerard

4

1 reference

24 May 2018

T Cerny

5

1 reference

24 May 2018

C Sessa

6

1 reference

24 May 2018

G Bastian

7

1 reference

24 May 2018

M Sarkany

8

1 reference

24 May 2018

J Schläpfer

9

1 reference

24 May 2018

B Giroux

10

1 reference

24 May 2018

S Leyvraz

11

1 reference

24 May 2018

publication date

1 November 1998

1 reference

24 May 2018

published in

Annals of Oncology

1 reference

24 May 2018

volume

9

1 reference

24 May 2018

issue

11

1 reference

24 May 2018

page(s)

1233-1242

1 reference

24 May 2018

Clinical multidrug resistance in cancer: a multifactorial problem

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Multiple-drug resistance in human cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Does P-Glycoprotein Predict Response to Chemotherapy, and If So, Is There a Reliable Way to Detect It?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Reversal of multidrug resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Clinical trials of P-glycoprotein reversal in solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

The influence of information on drug resistance on protocol design

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

New triazine derivatives as potent modulators of multidrug resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

The long QT syndrome. A review of recent molecular genetic and physiologic discoveries

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

The arrhythmogenic substrate of the long QT syndrome: genetic basis, pathology, and pathophysiologic mechanisms

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Ion channels--basic science and clinical disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008495919071

7 January 2021

Identifiers

DOI

10.1023/A:1008495919071

1 reference

24 May 2018

PubMed ID

9862055

1 reference

24 May 2018